Regulations.gov document
Cancer Clinical Trial Eligibility Criteria: Patients With Human Immunodeficiency Virus…
Notice · FDA-2019-D-0363 · posted Mar 13, 2019
Key facts
| Document ID | FDA-2019-D-0363-0001 |
|---|---|
| Title | Cancer Clinical Trial Eligibility Criteria: Patients With Human Immunodeficiency Virus, Hepatitis B Virus, or Hepatitis C Virus Infections; Draft Guidance for Industry; Availability |
| Document type | Notice |
| Subtype | Notice of Availability |
| Agency | FDA |
| Docket | FDA-2019-D-0363 |
| Posted | Mar 13, 2019 |
| Federal Register citation | 84 FR 9130 |
| FR document number | 2019-04572 |
| Comment period opens | Mar 13, 2019 |
| Comments due | May 14, 2019 |
| Effective date | Mar 13, 2019 |
At a glance
- 1–9 Pages
- No Open for comment
- 10–99 Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: